Business quality is the primary weakness (avg 25/100). Growth is the relative bright spot.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Growth
Above 10% CAGR, strong compounder
Above 10% CAGR, strong compounder
Business Quality & Capital Allocation
Heavy dilution above 5%
Expanded 3+pp, strong improvement
Net debt/FCF of 4.4x, high leverage
Below 8%, may not cover cost of capital
SourceQuality score computed from the 10-Q filed 12 Feb 2026, covering the period ending 31 Dec 2025, as reported to the SEC. Data last refreshed 25 Sept 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.
Peers
Services-Medical Laboratories · Pick stocks to compare with EXAS
Held by ETFs
EXAS is in 1 US ETF. The largest of them, with EXAS's weight in each:
Spot a number that looks wrong? Check it in EXAS's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing EXAS
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.